S
yncope is a sudden and transient loss of cons s sciousness associated with loss of postural tone from which recovery is spontaneous. 1 The most common cause of syncope in the general population is neurocardiogenic followed by primary arrhythmias. 2 In the presence of underlying heart disease, syncope is ass s sociated with a high rate of mortality.
Sudden cardiac death (SCD) is a witnessed cardiac arrest within 1 hour after the onset of acute symptoms or unexpected, unswitnessed death in a patient known to have been well within the previous 24 hours. 3 It ocs s curs with an approximate incidence of 1 per 1000 ins s habitants per year in the West. 4 The leading cause of SCD is ventricular fibrillation secondary to either acute ischemic events or underlying structural heart disease. However, no identifiable cause could be found in 10% of these victims during autopsy or during extensive evaluation of surviving cases. 4 Brugada syndrome is a new clinical entity first des s scribed by Brugada and Brugada in 1992 . 5 This syns s drome is responsible for approximately 4% of all SCD and 20% of SCD in patients without structural heart disease. 6 It is now considered an important cause of syncope among young patients.
Case
A 19syearsold male laborer, previously healthy, presents s ed to our emergency department due to sudden loss of consciousness and falling down after emotional stress. This lasted for few seconds as described by his coms s panion who witnessed the event. There was a history of brief palpitation, but he denies any chest pain, shortness of breath or seizures. The patient retained consciouss s ness rapidly, without headache or confusion, but could not recall the event exactly. He reported no similar ats s tacks before, and had no family history of syncope, epis s lepsy, or sudden unexplained death.
On examination the patient was a young, wellsbuilt and healthy male. His blood pressure was 137/82 mm Hg, heart rate was 124 beats per minute and he had a regular respiratory rate 16 breaths per minute and tems s perature of 36.8ºC. The heart, chest, abdomen and lows s er limb examination were normal. Neurological evalus s ation showed no focal deficit. The electrocardiogram showed sinus tachycardia, right bundle branch block pattern, and coving type STssegment elevation in the precordial leads V1, V2 and V3, which is characteristic of Brugada syndrome type 1 ( Figure 1A) .
The patient was hospitalized and investigations showed a normal creatinine kinase, troponin I, prolacs s tin, a negative toxicology screen, and other routine labos s ratory tests were normal. Xsrays, electroencephalogram and echocardiography were also within normal ranges. He was monitored at the Coronary Care Unit for four days. The ST segment elevation on the ECG returned to normal on the second day. No arrhythmias were res s ported during this period, but he was stratified in the highsrisk group for future arrhythmias.
A cardioverter defibrillator was implanted and he was discharged from the hospital 2 days later. He was followed up at our outpatient clinic after 6 days, at which time the ECG was normal ( Figure 1B ) and the patient was free of symptoms. He was seen again 3 months later due to viral pharyngitis and was asymptomatic but his ECG showed feversinduced STssegment elevation in V1 ( Figure 1C ).
DISCUSSION
Brugada syndrome is a type of cardiac membrane chans s nelopathy. The overall prevalence among the normal population is not established because the ECG is dys s namic and there are concealed forms of this syndrome. 7 Some studies report its prevalence to be about 0.05% to 0.6%. 8, 9 However, this prevalence is higher in south Asia than in Europe and the United States. 10 Brugada syndrome is a familial disease. About 60% of patients with Brugada syndrome have a family hiss s tory of sudden death or have family members with the ECG pattern of Brugada syndrome. Forty percent of patients have sporadic de novo mutations.
11 It is ins s herited as autosomal dominant disease with variable penetrance. Chen and coworkers described the genetic nature of the disease and its association to a mutation in the cardiac sodium channels. 12 About 80 mutations have been linked to the gene SCN5A. The exact electrophysiologic mechanisms of this syndrome are not fully understood. Prominent trans s sient outward potassium current (Ito) in the right vens s tricular epicardium results in marked shortening of the duration of the action potential causing a voltage gradis s ent within the endocardium which results in the ST els s evation on the ECG. The voltage gradient may result in reexcitation (phase 2 resentry) of the epicardium, which triggers ventricular arrhythmias. The sodium current (INa) opposes the potassium current (Ito) during phase 1 of the action potential. The faster inactivation of the sodium channel or the lack of function caused by the mutation explains why an unopposed current (Ito) bes s comes prominent and markedly shortens the duration of the action potential at the epicardial level. 17 Patients with Brugada syndrome may be asymptoms s atic and diagnosed accidentally, or present with syncope.
Unfortunately, in some patients, SCD might be the first presentation of the disease. It usually manifests during adulthood with a male predominance (male to female ratio, 8:1). The mean age of sudden death in victims of Brugada syndrome is about 35 to 40 years. 11 All clinical manifestations of Brugada Syndrome are attributed to ventricular tachyarrhythmias and their complications. Mostly, these arrhythmias occur at rest or during nights s time. 11 Brugada syndrome is diagnosed, after exclusion of structural heart disease, when there is a documented history of one of the electrocardiographic or clinis s cal events (Table 1) in association with a type 1 ECG pattern. 6 These ECG changes are variable over time, depending on the autonomic interaction and the ads s ministration of antiarrhythmic drugs. 18 Our patient fulfilled the diagnostic criteria for Brugada syndrome and needed no further invasive diagnostic tests. As he developed syncope, he most likely developed VT/VF that terminated spontaneously, which is a common pres s sentation in Brugada syndrome.
There are three ECG patterns used to diagnose Brugada syndrome. All have a Jswave amplitude ≥2 mm. Type 1 is characterized by the coving type STssegs s ment elevation in the precordial leads V1, V2 and V3, followed by T wave inversion. Type 2 shows a saddles s back STssegment elevation in leads V1, V2 and V3, but the downward displacement of the STssegment lies between the two elevations of the segment but does not reach the baseline and the Tswave could be positive or biphasic. Type 3 shows the same saddleback STssegs s ment as in type 2, but touches the baseline and the Ts wave is always positive. 19 The presence of a type 1 ECG pattern in asymps s tomatic patients is sufficient to diagnose this syndrome in the absence of other temporary conditions that may provoke ECG patterns that mimic Brugada syndrome ( Table 2 ). The pharmacologic provocation test is not indicated in these patients as it has neither diagnostic nor prognostic values yet. 19, 6 However, genetic testing is recommended to support the clinical diagnosis, and for early detection of relatives at potential risk. 6 On the other hand, in patients with type 2 and 3 ECG patterns, the drug challenge test is recommended to clarify the dis s agnosis. It is considered positive if type 2 or 3 converted to type 1, while conversion of type 3 to type 2 after the drug challenge is considered inconclusive. 19 The normal resting ECG is not sufficient to exclude the presence of Brugada syndrome, especially in family members of a patient with this syndrome or patients with unexplained syncope. Therefore, the drug provocas s tion test is recommended. It can be done by administers s ing a sodium channel blocker like ajmaline, flecainide, procainamide or pilsicainide under intensive monitors s ing conditions. The test is considered positive if there is an additional 1smm STssegment elevation in the right precordial leads V1, V2 and V3. 20 Placement of the right precordial leads in a superior position in the second intercostal space can increase the sensitivity of the ECG for detecting the Brugada phenotype in some patients with or without administering sodium channel blockers. 21 Contrary to the fact that vagal stimulation and bras s dycardia increase STssegment elevation in Brugada syns s drome, and that adrenergic stimulation or tachycardia decrease or may even normalize the STssegment elevas s tion, 22 our patient developed syncope after a stressful condition, which is characterized by sympathetic overs s stimulation. His ECG showed the characteristic ECG of Brugada syndrome while his heart rate was 125 beats per minute. On the other hand, there is growing evis s dence that Brugada syndrome is unmasked by fever, 23 which was noted in our patient.
Brugada syndrome is now considered different from arrhythmogenic right ventricular dysplasia/cardiomys s opathy (ARVD/C) in both its clinical presentation and genetic predisposition. 19 Drug challenge may be useful in discriminating between the two diseases.
24 While Brugada syndrome and sudden unexpected death syns s drome (SUDS) are the same entity, they share a lot of genetic, clinical, electrocardiographic and prognostic properties. 10 The list of drugs that can cause Brugadaslike STs segment elevation is expanding. These drugs include some antiarrhythmic, antianginal, psychotropic and ads s diction drugs, but it is not known if there is a genetic predisposition for these patients. 6 Programmed electrical stimulation (PES) reproducs s ibility induces VT or VF in almost all Brugada syns s drome patients with a history of aborted sudden death or syncope. 25 But, shall we extend the electrophysiologis s cal testing to the family members and asymptomatic pas s tients? Despite the belief that the inducibility of VT/ VF in electrophysiological studies may stratify asymps s tomatic patients with Brugada syndrome into the highs risk group, 26 and mandates the need for implantation of implantable cardioverter defibrillator (ICD), other Table 2 . eCg abnormalities mimicking brugada syndrome.
• 27s29 Brugada and coworkers found that inducibility of sustained vens s tricular arrhythmias during PES is a powerful predictor of outcome in Brugada syndrome. 30, 31 They concluded that symptomatic patients require protective ICD ims s plantation because of the high incidence of arrhyths s mic events, independent of the results of the PES, for which the test could simply be avoided. Asymptomatic patients can be reassured if they are nonsinducible, 31 while asymptomatic patients with positive PES should undergo ICD implantation. 32 So, EPS is recommended in all asymptomatic patients with Brugada syndrome.
Implantation of cardiac defibrillator is the only efs s fective intervention for preventing sudden cardiac death in Brugada syndrome. 25 It is recommended for all symptomatic patients. Although repeated episodes of polymorphic ventricular tachycardia can be treated with isoproterenol or quinidine, 11, 33 other antiarrhyths s mic drugs do not protect against sudden cardiac death in Brugada syndrome. 11 Indications for ICD are sums s marized in Table 3 .
Brugada syndrome is associated with a high prevas s lence of malignant arrhythmias and sudden death. The presence of Brugada ECG by itself is a risk for arrhyths s mic events, and normalization of the ECG during fols s low up does not indicate a better prognosis. 17 Patients with spontaneous Brugada ECG and a history of aborts s ed sudden cardiac death or syncope are at highest risk for development of these arrhythmias. 16 Asymptomatic individuals with spontaneous Brugada ECG are also at high risk for arrhythmic events if sustained ventricular arrhythmias are induced during EPS, while asymptoms s atic patients have a benign prognosis if the EPS is negas s tive. 
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